# CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

> **NCT05054257** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology and Blood Transfusion, Czech Republic** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma Refractory
- Non-Hodgkin's Lymphoma, Relapsed

## Interventions

- **DRUG:** Autologous CAR19 T lymphocytes

## Key facts

- **NCT ID:** NCT05054257
- **Lead sponsor:** Institute of Hematology and Blood Transfusion, Czech Republic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-02
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054257, "CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05054257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*